M. Irwin

Anti-vector immunoglobulin induced by retroviral vectors.

D. Martineau, W. Lee, D. Jolly, 1997, Human gene therapy.

Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates

S. Chada, V. Lee, D. Jolly, 1994, Journal of virology.

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal

O. Akilov, C. Querfeld, R. Pillai, 2017 .

A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

I. Flinn, M. Maris, S. Ansell, 2016 .

A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides.

O. Akilov, C. Querfeld, L. Johnson, 2017 .

Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Interim results of a multicenter Phase 1 trial

O. Akilov, C. Querfeld, R. Pillai, 2018, European Journal of Cancer.

Evidence for localization of biologically active recombinant retroviral vector to lymph nodes in mice injected intramuscularly.

S. Chada, S. Mento, W. Edwards, 1996, Gene therapy.